Synmosa Biopharma (4114.TWO) announced that its Board has approved a plan to acquire 15%–30% of Genovate Bio (4130.TWO) shares through a public tender offer at NT$24 per share — a 30% premium over Genovate's latest closing price of NT$18.45 (as of September 15).

This strategic move reflects Synmosa's commitment to expanding its pharmaceutical footprint and strengthening Taiwan's drug supply resilience.

Key Highlights 

• Premium Tender Offer: Up to 34.47 million shares (30%); minimum 17.23 million shares (15%).
• Timeline: Filing no later than Sept 16, with the tender period running until Oct 7 (21 days).
• Genovate Bio Profile: Founded in 1993 in Hsinchu Science Park, specializing in small molecule NCEs and generics, with PIC/S GMP-certified facilities.
• Strategic Collaboration: Shared resources and optimized processes to enhance efficiency, production flexibility, and economies of scale.
• Future Outlook: Strengthening Taiwan's pharmaceutical supply chain while gradually expanding into Asia-focused international markets. 

This acquisition not only fits Synmosa's long-term strategic vision but also aligns with Taiwan's government policy to promote industrial alliances, enhancing both domestic industry strength and international competitiveness. 

Read More, Learn More: